Cancer News: Gastric
Post-operative treatment intensification with chemoradiotherapy and post-operative chemotherapy induced similar outcomes to gastric cancer patients.
Palliative care showed to improve caregivers’ quality of life and mood creating a powerful positive feedback loop in families facing cancer.
Everolimus got approved by the FDA for the treatment of inoperable, locally advanced or metastatic neuroendocrine tumors of gastrointestinal or lung origin.
Pembrolizumab and nivolumab, two targeted immunotherapies, appeared effective in advanced gastric and esophageal cancers, two trials revealed.
The agent everolimus showed real promise in treating patients with nonfunctional neuroendocrine tumors of lung or gastrointestinal origin, a new study reveals.
The combination of olaparib (Lynparza) and paclitaxel improved overall survival in high-risk gastric cancer patients, a new study revealed.
A new drug has been approved to treat advanced stomach cancer or gastro-esophageal junction adenocarcinoma, following prior chemotherapy, in Europe.
Patients who receive radiation therapy, in addition to chemotherapy after surgery for stomach cancer appear to have better survival rates.
Israelis who were overweight as teenagers were more likely to have esophageal or gastroesophageal junction cancers later in life, researchers reported.
Weekly paclitaxel was as effective as biweekly irinotecan (Camptosar) as second-line therapy for advanced gastric cancer, researchers found.
Gastric cancer is quite treatable when diagnosed early, and researchers have taken a first step towards identifying sugars attached to proteins to help timely diagnosis.
Advanced gastric cancer patients' survival was prolonged with a combination of an experimental angiogenesis inhibitor and chemotherapy, in a large trial.
Combining standard 2nd-line chemotherapy with the targeted therapy ramucirumab improves survival, quality of life for patients with metastatic gastric cancer.
While recent reports warn about eating red and processed meat and its impact on cancer risk, a new paper authored by 23 scientists indicates uncertainties.
The latest research on stomach (gastric) cancer brings new hope for its early detection, thanks to the identification of four new biomarkers in patients’ blood.
The FDA has approved ramucirumab (an angiogenesis inhibitor, trade name: "Cyramza") for treatment of advanced gastric cancer or gastroesophageal adenocarcinoma.